Navigation Links
Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA,Vaccine Performance; Yields Antibody Responses Comparable to,Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- Vical Incorporated today announced that in a recently completed animal study, a DNA vaccine formulated with the company's patented Vaxfectin(TM) adjuvant and delivered by needle-free injection yielded significantly higher antibody responses than an unformulated DNA vaccine delivered by needle and syringe. In a separate animal study, electroporation following injection of unformulated vaccine yielded comparable improvements in antibody responses, but electroporation required anesthesia of the animals while needle-free injection of Vaxfectin(TM)-formulated vaccine was administered safely and tolerably without anesthesia.

"The dose-sparing and immunogenicity-enhancing capabilities of the Vaxfectin(TM) adjuvant have been demonstrated in a range of vaccine applications in various animal models," said Alain P. Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, "but the potential safety and tolerability advantages of Vaxfectin(TM) compared with alternative DNA delivery enhancement options are making it our preferred choice for new development projects. We look forward to beginning the initial human testing of a Vaxfectin(TM)-formulated DNA vaccine for pandemic influenza, anticipated in the second half of 2007, and to continued exploration of Vaxfectin(TM)'s use in optimizing efficacy and safety for future prophylactic or therapeutic applications."

Both studies were conducted in rabbits with DNA vaccines encoding cytomegalovirus (CMV) glycoprotein B (gB). The vaccines were either unformulated -- using standard phosphate-buffered saline (PBS) -- or formulated -- using the company's Vaxfectin(TM) adjuvant in PBS. Vaxfectin(TM)-formulated vaccines were injected with a needle-free device. Unformulated vaccines were injected with needle and syringe followed in some animals by electroporation using either a constant voltage multi
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
2. Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term Protection and Sterilizing Immunity in Nonhuman Primates
3. New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel
4. Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer
5. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
6. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
7. Phosphagenics Announces Positive Proof of Concept Results from Studies Utilizing Companys Dermal Drug Delivery Technology
8. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
9. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Inovio Biomedical Highlights Enhanced DNA Vaccine Potency with Electroporation DNA Delivery Technology and New Devices at Gene Therapy Meeting

Post Your Comments:
(Date:11/6/2009)...a., Nov. 6 In consultation with th...Consumer Healthcare, Division of McNEIL-PPC, Inc.,...ber of product lots of TYLENOL® Arthritis Pai...ed EZ-OPEN CAP. McNeil is initiating the recall af... associated with these lots that led to a small nu...
(Date:11/6/2009)...wswire/ -- Repossessions and liquidations of truck...er of 2009 declined as compared to similar figures... NasTrac Quarterly Index (NQI). The figures, cull...possessions and orderly liquidations, also indicat...nd printing equipment, offering mixed news on the ...
(Date:11/6/2009)...ewswire-FirstCall/ -- Derma Sciences, Inc. (OT...und care products, announced plans to release its ..., November 16, 2009. The Company will hold a confe... 11:00 am EST. Interested parties should call (866...onal), with passcode 81416481 to access the call. ...
Breaking Medicine Technology:McNeil Consumer Healthcare Announces Voluntary Recall of Certain Lots of TYLENOL(R) Arthritis Pain 100 Count with EZ-OPEN CAP 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 2NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 3NasTrac Quarterly Index Shows Decline in Trucking and Machine Tool Repossessions in Q3 2009 4Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 12373 1Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 12373 2Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 12373 3Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 12373 4Micromet Presents Update at ASCO 2009 on a Phase 1b Combination Study of Adecatumumab and Docetaxel 12373 5Intervention reduces delinquent teenage pregancy rates 47424 1Intervention reduces delinquent teenage pregancy rates 47424 2Intervention reduces delinquent teenage pregancy rates 47424 3AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis 4494 1AIMSPRO is Awarded TGA Orphan Status for the Treatment of Amyotrophic Lateral Sclerosis 4494 2
...MATEO, Calif., June 10 /PRNewswire-FirstCall/ - Ne...l company focused on developing and,commercializin... the,publication of Phase 3 data of its lead produ...The paper, titled, "Controlled Trial in,High-Conce...HIV,Neuropathy," will appear in the June 10, 2008 ...
...e 3 Once Weekly Investigational Diabetes Therapy A...hing from Exenatide Taken Twice a Day, SAN FRANCI... AMLN ), Eli Lilly and Company (NYSE: LLY ), and ...sults from a 52-week open-label clinical,study tha...ekly, a,long-acting release formulation of exenati...
Other Medicine Technology:NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 2NeurogesX Announces Publication of NGX-4010 Phase 3 HIV-Neuropathy Study Results in Neurology 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 2After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 3After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 4After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 5After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 6After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 7After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 8After One Year, Type 2 Diabetes Patients Taking Exenatide Once Weekly Sustained Improvements in Glycemic Control and Weight; DURATION-1 Presented at ADA 2008 9
(Date:11/8/2009)...ation,s largest network of Hispanic health advocat...eform in 2009 ,, WASHINGTON, Nov. 7 /PRNewswir...entatives showed they have heard the voice of Amer...re for America Act. Now the Senate must deliver, w...care reform," said Dr. Jane L. Delgado, President ...
(Date:11/8/2009)...ARP Praises House Passage of Health Care Reform Bi...edicare, improve coverage for all Americans ,,... the United States House of Representatives passed... legislation that would strengthen Medicare for se...s that prices millions of Americans out of afforda...
(Date:11/7/2009)...SHINGTON , Nov. 7 Sp...in support of H.R. 3962, the Affordable Health Car...islation later tonight. Below are the Speaker,s r...ow, is an historic moment for our nation and for A...f every party and political philosophy -- as far b...
(Date:11/7/2009)...USTON, Nov. 7 Members o...duce an emergency resolution rescinding the AMA,s ...icians that they are responsible to their PATIENTS...kes, Director of Policy for the Association of Ame...ine, a coalition of other medical groups. ,, "...
(Date:11/7/2009)...ON, Nov. 7 Americans United for Life Action endor...pak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smi... money from going to abortion in health care refor... and CEO Dr. Charmaine Yoest said, "Americans Unit...lsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Ame...
Breaking Medicine News(10 mins):Health News:National Alliance for Hispanic Health President and CEO Applauds House Action, Calls on Senate to Pass Health Reform in 2009 2Health News:AARP Illinois Key Vote News Alert 2Health News:AARP Illinois Key Vote News Alert 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:Americans United for Life Action Endorses a Vote for the Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-Lipinski-Smith Amendment and Sends Score Letter to House Members 2
...s and villagers, a woman who lost her husband to A...ted suicide in her Bihar home. Premila Devi,... her life by jumping into a well Saturday, just a ...usband's death," said a villager Nagender Singh. ...
...tee Sunday said medicines sold in shops would indi...xes from Oct 2. The decision was taken in a m...ministry of chemicals, fertilizers and steel. The ... medicines should be brought under price control i...
...determination test kits to counter online threats ...'s offer of 'Gender Mentor Home DNA gender testing...as sparked fears of a mass killing of unborn girls... Sunday. The central government's help would...
...ester when investigating for an alternative menopa...reated hot flashes as good as estrogen. Gabape...ting the flow of calcium in and out of the cells, ...years, report in the July Obstetrics and Gynecolog...
... PhD, and colleagues have come to the conclusion t...iness//. Kahneman shared the 2002 Nobel Prize for .... As Kahneman and colleagues have observed i...nse of] well-being, they are probably tempted to t...
...datory for food manufacturers to add folate to bre...rganisation that monitors food standards in New Ze...oposal by next month. Many live births and ...bies suffer lifelong moderate or severe disabiliti...
Other Medicine News:Health News:Gabapentin Reduced Menopausal Symptoms as Estrogen – Study Find 2Health News:Money Cannot Buy Happiness 2Health News:NZ To Opt For Folate Fortification Of Bread 2
ART REACHMicroPoint Design
... tips. Each box contains 1000 tips (5 bags of 200 ...bags of 50 tips). Also available in easy-to-open, ...Packs are sealed with a tamper-proof strip which c...amond Tips. Bulk Packs are closed using the rapid-...
1 mL Pipette Tip
Finntip Wide 100-1000ul
Medicine Products: